Raymond James Financial Services Advisors Inc. raised its position in Hologic, Inc. (NASDAQ:HOLX – Get Rating) by 9.7% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 25,682 shares of the medical equipment provider’s stock after buying an additional 2,279 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Hologic were worth $1,657,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Heritage Financial Services LLC purchased a new stake in Hologic in the 2nd quarter valued at about $27,000. Glassman Wealth Services grew its stake in Hologic by 59.6% in the 2nd quarter. Glassman Wealth Services now owns 415 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 155 shares during the period. Clear Street Markets LLC increased its position in shares of Hologic by 409.8% during the 2nd quarter. Clear Street Markets LLC now owns 520 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 418 shares during the last quarter. Salem Investment Counselors Inc. raised its stake in shares of Hologic by 163.9% during the 2nd quarter. Salem Investment Counselors Inc. now owns 549 shares of the medical equipment provider’s stock worth $38,000 after purchasing an additional 341 shares during the period. Finally, CX Institutional bought a new stake in shares of Hologic during the 2nd quarter worth $48,000. Hedge funds and other institutional investors own 95.17% of the company’s stock.
Analyst Upgrades and Downgrades
Several analysts have commented on HOLX shares. StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a research report on Friday, December 16th. Cowen dropped their price objective on Hologic from $88.00 to $86.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 1st. SVB Leerink raised their target price on Hologic from $85.00 to $90.00 and gave the stock an “outperform” rating in a research report on Thursday, January 12th. Mizuho upped their price target on Hologic from $75.00 to $77.00 and gave the company a “buy” rating in a research report on Tuesday, November 1st. Finally, William Blair reiterated an “outperform” rating on shares of Hologic in a research note on Tuesday, November 1st. Seven research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, Hologic has a consensus rating of “Moderate Buy” and an average target price of $78.75.
Hologic Stock Performance
Hologic (NASDAQ:HOLX – Get Rating) last announced its earnings results on Monday, October 31st. The medical equipment provider reported $0.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.20. The business had revenue of $953.30 million during the quarter, compared to analyst estimates of $861.68 million. Hologic had a net margin of 26.77% and a return on equity of 31.85%. Hologic’s revenue for the quarter was down 27.6% on a year-over-year basis. During the same period in the previous year, the business posted $1.61 earnings per share. As a group, analysts expect that Hologic, Inc. will post 3.48 earnings per share for the current fiscal year.
Insider Buying and Selling at Hologic
In other news, CFO Karleen Marie Oberton sold 14,545 shares of the company’s stock in a transaction dated Tuesday, November 1st. The stock was sold at an average price of $72.50, for a total value of $1,054,512.50. Following the completion of the transaction, the chief financial officer now directly owns 126,811 shares in the company, valued at approximately $9,193,797.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, General Counsel John M. Griffin sold 26,902 shares of the stock in a transaction on Monday, November 14th. The shares were sold at an average price of $76.12, for a total transaction of $2,047,780.24. Following the transaction, the general counsel now owns 168,944 shares of the company’s stock, valued at approximately $12,860,017.28. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Karleen Marie Oberton sold 14,545 shares of the business’s stock in a transaction on Tuesday, November 1st. The stock was sold at an average price of $72.50, for a total transaction of $1,054,512.50. Following the completion of the sale, the chief financial officer now directly owns 126,811 shares of the company’s stock, valued at $9,193,797.50. The disclosure for this sale can be found here. Company insiders own 1.54% of the company’s stock.
Hologic Company Profile
Hologic, Inc engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery.
- Get a free copy of the StockNews.com research report on Hologic (HOLX)
- Procter & Gamble Earnings: A Gamble Worth Taking
- Stocks Slide, Economic Report Paints Gloomy Picture For Economy
- What does Nu Holdings Stock Have To Do With Warren Buffett?
- J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
- Is Intel Stock On The Verge Of Breaking Out?
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.